Home › Funds › Parametrica Management Ltd › BCRX
Parametrica Management Ltd position in BCRX
BIOCRYST PHARMACEUTICALS INC · Health Care
Parametrica Management Ltd reported holding 15,401 shares of BCRX (BIOCRYST PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$128K, representing 0.11% of its reported portfolio and ranking #23 among its reported holdings. Parametrica Management Ltd first reported this position in Q3 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Parametrica Management Ltd's BCRX position evolved
Parametrica Management Ltd first disclosed a stake in BCRX in Q3 2026 at 15,401 shares (US$128K).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2026 | 15.40K | $128.29K | New |
About BCRX and 13F data
BCRX (BIOCRYST PHARMACEUTICALS INC) is a Health Care company. 46 other funds we track also report a position in BCRX — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$158.3M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$151.0M), TCG Crossover Management, LLC (US$110.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BCRX
- RA CAPITAL MANAGEMENT, L.P. 15.83M sh · $158.27M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 15.10M sh · $150.96M · Q2 2026
- TCG Crossover Management, LLC 11.02M sh · $110.21M · Q2 2026
- PERCEPTIVE ADVISORS LLC 10.31M sh · $103.09M · Q2 2026
- Vestal Point Capital, LP 8.30M sh · $83.00M · Q2 2026
- Jones Hill Capital LP 7.08M sh · $59.00M · Q3 2026
- Frazier Life Sciences Management, L.P. 4.01M sh · $40.09M · Q2 2026
- Kynam Capital Management, LP 2.52M sh · $25.23M · Q2 2026
- RICE HALL JAMES & ASSOCIATES, LLC 2.33M sh · $23.32M · Q2 2026
- Nantahala Capital Management, LLC 1.90M sh · $19.01M · Q2 2026
- Eversept Partners, LP 1.87M sh · $18.66M · Q2 2026
- Parkman Healthcare Partners LLC 1.62M sh · $16.24M · Q2 2026
More on Parametrica Management Ltd
FAQ
How long has Parametrica Management Ltd held BCRX?
Parametrica Management Ltd has disclosed BCRX holdings in 1 of the last 1 reported quarters, going back to Q3 2026.
What is Parametrica Management Ltd's current position in BCRX?
As of Q3 2026, Parametrica Management Ltd holds 15.40K shares of BCRX (BIOCRYST PHARMACEUTICALS INC), valued at $128.29K, representing 0.11% of its reported portfolio and ranking #23.
Has Parametrica Management Ltd been buying or selling BCRX?
In the latest 13F filing (Q3 2026), Parametrica Management Ltd newly opened its position in BCRX.
Which other funds hold BCRX?
Other major institutional holders of BCRX include RA CAPITAL MANAGEMENT, L.P., DEERFIELD MANAGEMENT COMPANY, L.P., TCG Crossover Management, LLC, among 46 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.